|Articles|October 15, 2002
- BioPharm International-10-01-2002
- Volume 15
- Issue 10
Biotech Will Recover!
Author(s)G. Steven Burrill
by G. Steven Burrill, Burrill & Company Beleagured by bad news since the start of the year, biotech is barely registering a pulse on Wall Street . . . but it's hardly time to write the industry's obituary.
Advertisement
Articles in this issue
about 23 years ago
FDA Launches Major CGMP Reviewabout 23 years ago
Process Validation: How Much to Do and When to Do Itabout 23 years ago
GMPs and Pharmaceutical Labelingabout 23 years ago
Revolutionizing Biologics RegulationNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How Mitigation and Maintenance Protect Against Future Risk
2
GSK and Oxford BioTherapeutics Drive Antibody-Based Cancer Drug Discovery at Industry Scale
3
FDA Decision Accelerates Rare Disease Gene Therapy Regulatory Pathways
4
New Cord Blood Stem Cell Approval Alters Biopharma Manufacturing Priorities
5
